In 2004, the company was restructured from a Shenzhen state-owned enterprise into the family of China National Pharmaceutical Group. Through capital operation and resource integration, the company's operating strength and business performance have developed significantly, with sales revenue increasing more than 9 times compared with 2004, total profit increasing 20 times compared with 2004, and the average annual growth rate of main business income reaching more than 20%, by the end of 2011, the company's sales revenue exceeded 15 billion yuan.
Sopharmaceuticals Unanimous Pharmaceutical Industry integrates product research and development, production of raw materials and preparations, and marketing, and its products mainly cover the fields of cephalosporin antimicrobials, respiratory drugs
, digestive drugs, cardiovascular and cerebral vascular drugs, and antitumor drugs, etc. Its wholly-owned enterprise Shenzhen Zhijun Pharmaceutical Co. Its wholly-owned enterprises Shenzhen Zhijun Pharmaceutical Co., Ltd. and Sinopharm Holding Shenzhen Traditional Chinese Medicine Co., Ltd., its holding company Suzhou Zhijun Wanqing Pharmaceutical Co., Ltd. and its shareholding company Shenzhen Wanle Pharmaceutical Co. The key varieties of cefuroxime, cefixime, cefoxitin, cefminox, cefpertan and other raw materials or preparations in the market segments in a leading position, and has six single product sales of more than 100 million yuan products. Among them, Shenzhen Zhijun Pharmaceutical Co., Ltd. is the first manufacturer of cephalosporin injection preparations whose independent product registration has passed the EU GMP certification, and is ranked among the top 50 pharmaceutical industry enterprises in China.
The pharmaceutical distribution business of Sinopharm ranks the top in Guangdong and Guangxi provinces, and is listed among the top 20 pharmaceutical commercial companies in China, with its subsidiaries located in Shenzhen, Guangzhou, Dongguan, Foshan, Zhanjiang, Meizhou, Zhaoqing, Huizhou, Nanning, Liuzhou, Jiangmen, Guilin, Yulin, Baise, etc. The business covers a wide range of modes, including pure sales in hospitals, commercial transfers, fast-approval of medicines, and terminal distribution, etc., and it owns a perfect national commercial network and deep-penetration terminal in the southern region. It has a perfect national commercial network and a y penetrated terminal market network in the southern region, a professional pharmaceutical logistics center with the highest degree of automation and the strongest service capacity in South China, and is the first enterprise in South China to be granted the qualification of third-party pharmaceutical logistics. Sinopharm's distribution is fully committed to building an intelligent supply chain, realizing systematic integration of logistics, capital flow and information flow from manufacturers to end users, with information available everywhere and business processed in real time, fully meeting the needs of all parties and creating a new distribution business model.